Saturday, November 23, 2024

Zynex, Inc Announces New Therapy Products

Zynex, Inc., an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced the addition of three new therapy products centered around pain management. The new products include Zynex Pro Thoracic Lumbar Sacral Orthosis (“TLSO”), a dual-purpose back brace for the mid and lower spine; Zynex Pro Wrist, a wrist brace for a broad spectrum of wrist-related pain management including carpal tunnel syndrome; and Zynex Cryoheat, a localized cold or hot fluid therapy system for home or hospital use.

Thomas Sandgaard, Founder and CEO, explains, “As we continue to build out our sales force in pain management, we are continually looking to add to our product suite in complementary ways. Combining these products with our industry-leading prescription strength pain management device, the NexWave builds upon our holistic, non-invasive approach to pain management.”

Also Read: Mouser Electronics Shares the Revolutionary Power of Digital Therapeutics in Latest Empowering Innovation Together Series

Zynex is an engineers, manufactures and markets neuro-diagnostics, stroke rehabilitation, pain management and cardiac monitoring devices within three subsidiaries. Zynex Medical is a provider of electrotherapy products for home use. Zynex Monitoring Solutions develops products for cardiac monitoring for use in hospitals. Zynex NeuroDiagnostics develops devices for EMG and EEG diagnostic applications within neurology disciplines. Zynex Medical’s product line is fully developed, FDA/CE cleared, commercially sold, and has been developed to uphold the Company’s mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex Monitoring Solutions and Zynex NeuroDiagnostics are currently both in the development stages without any significant revenues.

SOURCE: PRNewswire

Subscribe Now

    Hot Topics